Phytomedicine
Volume 10, Supplement 4 , Pages 7-17, 2003

Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis:

A randomised, double-blind, placebo-controlled trial

  • Heinrich Matthys

      Affiliations

    • Lungs at Home, Freiburg i. Br., Germany
    • Corresponding Author InformationHeinrich Matthys, Lungs at Home, Hochrüttestraße 17, D-79117 Freiburg, Germany; Tel.: +49-7 61-628 22; Fax: +49-7 61-600 85 80
  • ,
  • Reinhard Eisebitt

      Affiliations

    • ClinResearch GmbH, Cologne, Germany
  • ,
  • Bettina Seith

      Affiliations

    • Research Center HomInt, Karlsruhe, Germany
  • ,
  • Marianne Heger

      Affiliations

    • Research Center HomInt, Karlsruhe, Germany

Summary

Background: New evidence-based treatment options are required to avoid antibiotic overuse in acute bronchitis and to replace potentially inefficacious initial antibiotic treatment.

Objective: To evaluate the efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) compared to placebo in patients with acute bronchitis.

Design: Randomized, double-blind, placebo-controlled trial using a multi-stage adaptive design.

Setting: 36 primary care physicians (investigators) at the out-patient care setting.

Patients: 468 adults with acute bronchitis present ≤48 hours, Bronchitis Severity Score (BSS) ≥5 points, and informed consent.

Intervention: EPs 7630 or placebo (30 drops three times daily) for 7 days.

Measurement: The primary outcome criterion was the change of BSS on day 7.

Results: The decrease of BSS from baseline to day 7 was 5.9 ± 2.9 points under EPs 7630 (n = 233), and 3.2 ± 4.1 points under placebo (n = 235). The 95% CI for the difference of effects between the two treatment groups (EPs 7630 minus placebo) was calculated as [–3.359; –2.060] showing a significant superiority of EPs 7630 compared to placebo on day 7 (p < 0.0001). Working inability decreased to 16% in the EPs 7630 group compared to 43% in the placebo group (p < 0.0001). In addition, the duration of illness was significantly shorter for patients treated with EPs 7630 compared to placebo (p < 0.001). Within the first four days, onset of treatment effect was recognized in 53.6% of patients under EPs 7630 compared to 36.2% of patients under placebo, only (p < 0.0001). Adverse events (AEs) occurred in 36/468 patients (EPs 7630: 20/233 patients, placebo: 16/235 patients). All events were assessed as non-serious.

Conclusion: EPs 7630 was superior in efficacy compared to placebo in the treatment of adults with acute bronchitis. Treatment with EPs 7630 clearly reduced the severity of symptoms and shortened the duration of working inability for nearly 2 days.

Key words:  Acute bronchitis , randomized controlled trial , double-blind , placebo-controlled clinical trial , herbal medicine , extract of Pelargonium sidoides , EPs 7630

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0944-7113(04)70346-3

doi:10.1078/1433-187X-00308

Phytomedicine
Volume 10, Supplement 4 , Pages 7-17, 2003